Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-12-03 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
独立董事关于第二届董事会第十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting (the 15th meeting of the 2nd board) about an investment transaction involving convertible bonds and related party transactions. It references compliance with stock exchange listing rules and company bylaws. The content focuses on the board's review and approval of a transaction, including risk assessment and conflict of interest management. It does not contain financial statements, earnings data, or detailed financial analysis. It is a governance-related document concerning board decisions and opinions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2019-12-03 Chinese
关于以可转股债权方式对外投资事项展期暨关联交易公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Co., Ltd. regarding the extension of an investment in the form of convertible debt in an affiliated company, Shenzhen Early Know Technology Co., Ltd. It includes comprehensive information about the investment terms, related parties, financial data, risk assessments, and approvals from the board, independent directors, and supervisory board. The document focuses on a specific financing transaction involving convertible debt investment and related party transactions, with no indication of it being a full annual or quarterly report, earnings release, or other financial statement. It is not a simple announcement of a report publication but a substantive disclosure of a capital/financing update and related transaction details. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2019-12-03 Chinese
第二届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is titled as a resolution announcement from the company's board of directors (第二届董事会第十五次会议决议公告), detailing the convening and voting results of a board meeting held on December 3, 2019. It includes information about the meeting procedures, agenda items such as approval of an investment extension and the scheduling of a shareholders' meeting, and voting outcomes. There is no detailed financial data or comprehensive report content. The document is a formal announcement of board meeting resolutions rather than a full management report, annual report, or financial statement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2019-12-03 Chinese
关于召开2019年第五次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed announcement regarding the convening of the 2019 fifth extraordinary general meeting of shareholders for Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures (both onsite and online), registration details, agenda items, and proxy voting instructions. There is no financial data, earnings information, or report content. The document serves as a notice or invitation to shareholders to participate in the meeting and vote on specific proposals. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2019-12-03 Chinese
独立董事关于第二届董事会第十四次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting matter about waiving the preemptive rights for capital increase in a wholly-owned subsidiary and related party transactions. It references compliance with stock exchange listing rules and company articles but does not contain financial statements or detailed financial data. The document is short (725 characters) and focuses on board-level opinions and approvals related to corporate governance and transactions. This fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. It is not an annual report, audit report, or financial report, nor is it a regulatory filing or announcement of a report publication. Therefore, the classification is MANG with high confidence.
2019-11-29 Chinese
第二届监事会第十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the 13th meeting of the 2nd Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It details the meeting's convening, attendance, and the approval of a proposal regarding the waiver of the preemptive rights for capital increase in a wholly-owned subsidiary. The document includes voting results and confirms compliance with relevant laws and company articles. It is a corporate governance-related announcement about board/supervisory committee decisions rather than a full report, financial statement, or regulatory filing. The document length is short (1450 characters), and it is not a report publication announcement or certification. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or management bodies.
2019-11-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.